NewLimit
Biotechnology company developing therapeutics to extend human healthspan.
- Business Profile
- Founders & Team5 sources scanned
- Market Size6 sources scanned
- Competitor Research5 sources scanned
- Funding8 sources scanned
- Momentum8 sources scanned
- Customer Sentiment4 sources scanned
- AI Visibility
- Risks & Red Flagspublic record checked
Summary
Worth a closer lookNewLimit is a privately financed longevity therapeutics company positioned in the biology-first tranche of the anti‑aging field, pursuing translational programs to extend human healthspan. It sits alongside peers such as Oisin, Retro Biosciences, Alkahest, Junevity and Insilico Medicine but is noticeably less public about modality and lead program specifics; that opacity is the single biggest tension. Funding momentum is substantial — a sequence of rounds through 2025–2026 culminating in a $435M Series C led by Founders Fund (press valuation ≈ $3.1B) — and the company signals an operational inflection with plans for its first liver clinical trial next year. The combination of deep capital, a ~40–52 headcount and named founders (CEO Jacob Kimmel; cofounders Brian Armstrong and Blake Byers) justifies a first meeting to probe program clarity, IND readiness, IP and the stated B2C commercialization approach.
Bull case
- Strong investor conviction: four disclosed financings totaling $682.2M including a $435M Series C led by Founders Fund (June 2, 2026) at an alleged ~$3.1B valuation.
- Near-term clinical inflection: company public statements/press indicate plans to start its first liver clinical trial next year, creating a tangible milestone to validate translational claims.
- Founding and leadership bench: publicly identified team includes CEO/President Jacob Kimmel and cofounders Brian Armstrong and Blake Byers, and an operating headcount reported in the ~40–52 range — enough scale to execute IND/early clinical programs.
- Market exposure consistent with a large opportunity: targets the longevity‑therapeutics market with a TAM cited at USD 23.24B (2024), placing NewLimit in a multi‑$10B competitive arena where successful translation commands premium value.
Watch-outs
- Low program transparency: unlike named peers (Oisin, Retro, Alkahest, Junevity, Insilico), NewLimit has not published clear modality, target, or preclinical data publicly, making scientific and regulatory risk hard to assess.
- No public customer or commercial traction: there are no independent customer reviews, pricing, SAM/SOM, or real-world performance signals to validate a B2C commercialization claim.
- Business model ambiguity: company is listed as B2C while operating as a therapeutic developer — go‑to‑market, pricing, and regulatory pathways for that model are unspecified and could be a material operational risk.
- Valuation versus disclosure mismatch: a ~$3.1B press valuation after a $435M Series C elevates execution expectations and increases downside if the planned liver trial or IND timelines slip.
Questions for the founder
- 1What is the lead program's modality, target indication, and most recent preclinical efficacy/tox data you can share?
- 2What is the IND/clinical timeline and primary endpoints for the planned liver trial next year, and what data would be a go/no‑go?
- 3How does NewLimit envisage a B2C commercialization model for therapeutics (pricing, channel, regulatory approach) versus more typical B2B/partnered routes?
- 4Post‑Series C, what is the current runway and planned use of proceeds (R&D, CMC, clinical ops, M&A, hiring)?
- 5What defensible IP and freedom‑to‑operate positions separate NewLimit from Oisin, Retro and other biology-first competitors?
Company profile
Pricing
Not publicly disclosed. The company website does not list its pricing on any of the 6 pages we read.
Target segments
Product suite
- Epigenetic reprogramming medicines
Therapeutics that restore youthful function to aged cells by identifying combinations of transcription factors to reverse cellular aging without changing cell identity.
- Immunology Program
Program to rejuvenate T cell function in older adults to reduce age-related susceptibility to infections, cancer, and autoimmunity.
- Vascular Program
Program focused on restoring endothelial cell function to maintain vascular health; initial targets include chronic kidney disease.
- Functional genomics & ML discovery platform
Discovery platform leveraging functional genomics, pooled perturbation screening, and machine learning to identify transcription-factor combinations for cellular rejuvenation.
Stats they publish
Social accounts
Founders & Team
3- Jacob KimmelFounderCEO & PresidentComputational biologist.
- Brian ArmstrongFounderCo-founderCoinbase CEO and co-founder.
- Blake ByersFounderCo-founderFormer GV partner and bioengineer.
NewLimit's publicly identified founding team comprises Brian Armstrong and Blake Byers (co‑founders) and Jacob Kimmel, who serves as CEO & President. Aggregator profiles report a headcount in the ~40–52 range.
- Founders and Kimmel’s CEO title are stated on NewLimit's official blog and corroborated in press; other individual executives that appear on aggregator pages (e.g., Kate Franz, Cathy O'Hare, Alex Kim) are not clearly attributed on the company's own site in the provided sources and were therefore omitted.
- Headcount is taken from Tracxn (52) and other aggregators report slightly different figures (37–51); no official company team page with a full roster or a single authoritative headcount was available in the provided sources.
Market Size
Published market research estimates the global 'longevity therapeutics' market at roughly USD 23.24B in 2024 (DataM Intelligence), with other reputable reports showing similar multi‑$10B baselines and varying CAGR assumptions. A defensible SAM cannot be produced because NewLimit has not published pricing/ACV or a grounded addressable customer count; therefore SAM and SOM are left null.
- DataM Intelligence ↗USD 23.24 Billion in 2024; projected to reach USD 43.72 Billion by 2033, 7.8% CAGR (2025-2033) · Global · 7.8% CAGR
- Allied Market Research ↗USD 25.1 billion (2020), projected to reach USD 44.2 billion by 2030, 6.1% CAGR (2021-2030) · Global · 6.1% CAGR
- SNS Insider ↗USD 27.61 Billion (2025); projected to reach USD 67.03 Billion by 2035, 9.41% CAGR (2026-2035) · Global · 9.41% CAGR
- Target geographyGlobalNewLimit (company stated geography/market focus)
- Target customer segmentsPatients, clinicians, research institutions, pharma partnersNewLimit (company description)
- Company pricing / ACVNo public pricing or annual contract value (ACV) available for NewLimit; cannot derive per‑customer revenueNewLimit (no published pricing/ACV disclosed)
- Why SAM not sizedNo grounded customer counts or company ACV available to perform bottom‑up SAM; published market splits (e.g., supplements vs therapeutics) vary and are not reported with the granularity required to derive a reliable SAM for NewLimit's therapeutic focusMarket reports cited above; NewLimit (no pricing)
- Top‑down TAM figures use different definitions (some include supplements, wellness products, and diagnostics). DataM Intelligence's 'longevity therapeutics' figure includes a broad set of interventions; if NewLimit focuses only on advanced therapeutics (e.g., senolytics/gene therapies) the relevant sub‑segment is smaller but not separately published.
- SAM was not estimated because no public company pricing (ACV) or a grounded count of target customers was found; producing a bottom‑up SAM without those inputs would be a guess.
- SOM left null because SOM requires a grounded SAM and a justified obtainable‑share assumption tied to product, pricing, stage and traction.
- Some market reports are paywalled or use differing category boundaries and forecast windows; reported CAGR and base‑year figures therefore vary across publishers.
- All figures are reported in USD and reflect the publishers' years as cited above.
Competitors
Top 5Landscape splits between biology-first therapeutic developers (senolytics, reprogramming, plasma factors) and AI-driven discovery platforms. NewLimit sits among biology-focused healthspan therapeutics, less publicly detailed but competing on translational programs against platform specialists.
- Oisin Biotechnologiesoisinbio.com ↗Develops senolytic gene therapies via DNA-targeted LNPs; NewLimit overlaps on longevity therapeutics but is broader and less public, differing in modality and target specificity.
- Retro Biosciencesretro.bio ↗Pursues cellular reprogramming and autophagy-based longevity therapies; NewLimit competes in aging therapeutics but appears less public about mechanism and program specifics.
- Alkahestalkahest.com ↗Develops plasma-derived proteomic therapies for age-related diseases; NewLimit targets healthspan therapeutics more broadly, while Alkahest specializes in plasma factor translation.
- Junevityjunevity.com ↗Builds AI-driven cell-reset/immune-rejuvenation therapeutics via RESET platform; NewLimit overlaps on rejuvenation aims but differs in modality and undisclosed program focus.
- Insilico Medicineinsilico.com ↗AI-first drug discovery for aging-related targets; NewLimit focuses on advancing therapeutics to clinic, while Insilico excels at computational target ID and lead generation.
Funding
- Series A$72.2MMay 08, 2023Dimension Venture PartnersFounders FundKleiner PerkinsEric SchmidtElad GilGarry TanFred EhrsamTracxn ↗
- Series B$130MMay 02, 2025Kleiner Perkins leadDaniel GrossKhosla VenturesFounders FundDimension Venture PartnersGarry TanPatrick CollisonHuman CapitalValor Equity PartnersBrian ArmstrongNat FriedmanElad GilTracxn ↗
- Convertible Note$45MOct 20, 2025AbstractBoost VCDimension CapitalCrunchbase ↗
- Series C$435MJune 02, 2026Founders Fund leadThrive CapitalGreenoaksQuiet CapitalKleiner PerkinsAbstractNat Friedman/Daniel GrossValor Equity PartnersEli Lilly VenturesHuman CapitalNewLimit Blog ↗
NewLimit has publicly disclosed four financings: a Series A in 2023 (~$72.2M), a $130M Series B in May 2025, a $45M financing in October 2025, and a $435M Series C led by Founders Fund in June 2026 that the press reports values the company at about $3.1B.
- Some sources disagree on labels and amounts for pre-Series C rounds: Tracxn lists a $72.2M Series A (May 2023) while other summaries reference a $40M 2023 Series A; the Oct 2025 $45M tranche is reported both as a Series B top-up (Tracxn) and as a convertible note (Crunchbase).
- Total raised is the sum of the dated rounds above ($682.2M). Databases and press summaries vary; the itemized rounds above are grounded only in the cited texts and may not represent every undisclosed or secondary transaction.
- Latest valuation ($3.1B) is reported by press coverage (STAT/CryptoBriefing/Investing) after the Series C; the company blog confirms the Series C amount but does not state the valuation.
- Investor lists for some rounds are reported differently across sources; investors[] is the deduplicated union of named participants in the provided texts.
Momentum
- FundingJune 02, 2026Raised $435M Series C led by Founders Fund (post-money ~$3.1B)NewLimit (company blog) ↗
- PressJune 2, 2026Announced plans to launch its first clinical trial of a liver medicine after the $435M raiseSTAT ↗
- PressJun 2, 2026Said it plans to push into a phase 1 trial next year (company statement reported)Fierce Biotech ↗
- FundingOct 20, 2025Raised $45M via a convertible noteCrunchbase ↗
- FundingMay 02, 2025Raised $130M Series B (May 2025)Tracxn ↗
- FundingMay 08, 2023Raised $72.2M Series A (May 2023)Tracxn ↗
Multiple financings over 2025–2026 culminating in a $435M Series C (June 2, 2026) and contemporaneous press reporting that NewLimit plans its first liver clinical trial next year indicate accelerating operational and fundraising momentum.
- Most recent public signals are financing and press coverage around the June 2026 Series C; independent clinical data or regulatory filings are not present in these items.
- Several funding entries are drawn from third‑party databases (Tracxn, Crunchbase) rather than standalone primary press releases.
- Multiple outlets report the same June 2, 2026 Series C; coverage density is high but partly duplicative.
Customer Sentiment
There are no independent public customer reviews of NewLimit’s therapeutics or commercial experience. Available public signals are company blog posts and news coverage about fundraising and preclinical progress, plus a Glassdoor listing that appears to be for a differently named employer and reflects employee sentiment rather than customer feedback.
No customer-facing product is on the market; press coverage documents preclinical progress and upcoming human studies but contains no end‑user or patient reviews.
The only review-style content found is a Glassdoor employer profile listed as “New Limits” (space) with 14 ratings and a 5.0 snapshot; the name mismatch and the fact these are employee reviews prevent treating this as customer sentiment for NewLimit.
Company-owned blog posts (NewLimit Blog) report internal milestones and should not be treated as independent customer feedback.
Insufficient independent third-party customer reviews to judge customer sentiment — common for early-stage, preclinical biotech and B2B companies.
AI Visibility
We ask ChatGPT WITH web search about the company and show its answers plus the sources it cited — the real AI-search experience. The key signal is share of voice: does the company come up when AI is asked about its space, not just when asked by name.
Models asked ChatGPT · web search
Accuracy of what AI said: Accurate — Correctly identifies NewLimit as a 2021-founded biotech focused on epigenetic reprogramming to extend healthspan, co-founded by Brian Armstrong and Blake Byers, and reports funding, headcount, program focus, and investor names consistent with public disclosures.
NewLimit is a biotechnology company dedicated to extending human healthspan by developing epigenetic reprogramming therapies aimed at reversing cellular aging. The company was co-founded in 2021 by Brian Armstrong, CEO of Coinbase, and Blake Byers, a former General Partner at GV (Google Ventures). (newlimit.com)
As of May 2025, NewLimit employed 34 scientists, engineers, and operators, with over 90% serving in technical roles. (newlimit.com) The company has raised significant funding, including an initial commitment of $110 million from the founders, a $40 million Series A round in 2023, and a $130 million Series B round in 2025 led by Kleiner Perkins. (techcrunch.com)
NewLimit's research focuses on developing epigenetic reprogramming medicines to treat age-related diseases by restoring youthful function in aged cells. Their initial programs target the liver, immune system, and vasculature, aiming to address conditions such as alcohol-related liver disease, autoimmune diseases, and chronic kidney disease. (newlimit.com)
The company's approach involves using functional genomics, pooled perturbation screening, and machine learning models to understand and reverse the biology of epigenetic aging. (newlimit.com)
Notably, NewLimit has attracted a diverse group of investors, including Kleiner Perkins, Dimension Capital, Founders Fund, Nat Friedman, Daniel Gross, Khosla Ventures, and Eli Lilly & Company. (newlimit.com)
In summary, NewLimit is a well-funded biotechnology company co-founded by prominent figures in the tech industry, focusing on developing therapies to reverse cellular aging and extend human healthspan.
Here is a concise list of notable companies in the longevity therapeutics space:
- Altos Labs: Founded in 2021 and backed by Jeff Bezos, Altos Labs focuses on cellular rejuvenation using Yamanaka factors to reprogram cells to a youthful state. (scispot.com)
- Calico Life Sciences: A subsidiary of Alphabet Inc., Calico aims to understand the biology of aging and develop therapeutic interventions for age-related diseases. (strategicmarketresearch.com)
- Unity Biotechnology: Specializes in senescence-targeted therapies, developing drugs to eliminate senescent cells that contribute to aging and disease. (strategicmarketresearch.com)
- Insilico Medicine: Combines AI with biology to discover novel longevity treatments, with its platform yielding drug candidates for age-related diseases. (scispot.com)
- AgeX Therapeutics: Develops regenerative medicine using pluripotent stem cells, focusing on tissue engineering and cell-based therapies. (scipublications.com)
- Genflow Biosciences: Focuses on gene therapies targeting aging processes, utilizing a SIRT6 variant found in centenarians. (en.wikipedia.org)
- Life Biosciences: Develops epigenetic medicines for aging and age-related diseases, with FDA clearance for human trials of its investigational drug ER-100. (en.wikipedia.org)
- Juvenescence: Takes a portfolio approach to longevity, investing in and developing multiple therapeutic modalities including small molecules, cell therapies, and gene therapies. (geneediting101.com)
- Gero: Utilizes AI-driven drug discovery to develop therapies targeting aging and age-related diseases, with collaborations with major pharmaceutical companies. (en.wikipedia.org)
- BioAge Labs: A clinical-stage biotechnology company developing a pipeline of therapies to extend healthy lifespan by targeting the molecular causes of aging. (ventureradar.com)
The longevity therapeutics sector is rapidly evolving, with several companies at the forefront of developing treatments aimed at extending healthy human lifespan. Here are some notable organizations in this field:
1. Altos Labs
Founded in 2021 and backed by Jeff Bezos, Altos Labs focuses on cellular rejuvenation through epigenetic reprogramming. By 2026, the company has initiated human clinical trials targeting neurodegenerative and immune-related aging disorders. (scispot.com)
2. Calico Life Sciences
A subsidiary of Alphabet Inc., Calico Life Sciences is dedicated to understanding the biology of aging and developing therapeutic interventions. The company has partnered with AbbVie to create treatments targeting cellular aging processes, focusing on age-related diseases like Alzheimer's and heart disease. (strategicmarketresearch.com)
3. Unity Biotechnology
Unity Biotechnology is at the forefront of senolytic drug development, aiming to eliminate senescent cells that contribute to aging and age-related diseases. Their lead product, UBX0101, targets conditions such as osteoarthritis, Alzheimer's, and retinal degeneration. (strategicmarketresearch.com)
4. Insilico Medicine
Combining artificial intelligence with biology, Insilico Medicine focuses on discovering novel longevity treatments. Their platform, Pharma.AI, has produced drug candidates for age-related diseases like idiopathic pulmonary fibrosis, with their first AI-discovered drug in Phase 2 trials as of 2026. (scispot.com)
5. BioAge Labs
BioAge Labs is a clinical-stage biotechnology company developing therapies to extend healthy lifespan by targeting the molecular causes of aging. They utilize a platform that analyzes human aging data to identify and develop drug candidates. (ventureradar.com)
6. AgeX Therapeutics
AgeX Therapeutics focuses on developing medical therapeutics related to human longevity, including regenerative medicine and cellular therapies. The company aims to address age-related degenerative diseases by advancing technologies in cellular immortality and tissue regeneration. (en.wikipedia.org)
These companies represent a segment of the innovative efforts underway in the longevity therapeutics space, each contributing unique approaches to understanding and potentially extending human healthspan.
The assistant did not surface NewLimit unprompted in its lists of notable longevity-therapeutics companies, but when asked directly it produced a description that matches public sources and appears reliable for VC due diligence baseline checks.
- AI outputs (especially unprompted category/recommendation lists) vary by run and often rely on third-party lists that can omit newer entrants.
- Many details come from company disclosures and press coverage; those sources may emphasize accomplishments and should be cross-checked with primary filings or direct conversations for investment decisions.
- Web-indexing and curated lists can lag for recently founded or stealth-funded companies, which can explain omission from unprompted lists.
Risks & Red Flags
No material public risk signals found. An absence of public concerns isn’t a clean bill of health — early or private companies may simply not generate coverage.
No independent third‑party source URLs specifically reporting risks for NewLimit were identified.
A lack of public reporting does not prove absence of issues; private companies and early‑stage biotechs often generate little public footprint even when material events occur.
Compiled by AlgoTurk from public web sources · . Not investment advice.